About Probable protein phosphatase 1N
Probable protein phosphatase 1N (PPM1N) is a protein
from Homo sapiens identified by UniProt accession
Q8N819, 430 residues long.
MolForge cross-references it against 0 known binders and
19 disease associations.
Target properties
| Protein name | Probable protein phosphatase 1N |
| UniProt accession | Q8N819 |
| Gene | PPM1N |
| Organism | Homo sapiens |
| Length | 430 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (19)
Diseases linked to this target (Open Targets).
- Spastic paraplegia · score 0.52
- Autosomal dominant spastic paraplegia type 12 · score 0.50
- hereditary spastic paraplegia 12 · score 0.50
- genetic disorder · score 0.19
- hereditary spastic paraplegia · score 0.18
- PHF-tau measurement · score 0.16
- heel bone mineral density · score 0.14
- neurofibrillary tangles measurement · score 0.14
- grip strength measurement · score 0.08
- drug use measurement · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8N819-F1 | alphafold | PREDICTED | 87.42 | — |
Amino-acid sequence (430 residues)
MAVLARQLQR LLWTACKKKE REKEGREEEE EEEAGRRAPE GPRSLLTAPR RAQRPHGGAE ASGGLRFGAS AAQGWRARME DAHCTWLSLP GLPPGWALFA VLDGHGGARA ARFGARHLPG HVLQELGPEP SEPEGVREAL RRAFLSADER LRSLWPRVET GGCTAVVLLV SPRFLYLAHC GDSRAVLSRA GAVAFSTEDH RPLRPRERER IHAAGGTIRR RRVEGSLAVS RALGDFTYKE APGRPPELQL VSAEPEVAAL ARQAEDEFML LASDGVWDTV SGAALAGLVA SRLRLGLAPE LLCAQLLDTC LCKGSLDNMT CILVCFPGAP RPSEEAIRRE LALDAALGCR IAELCASAQK PPSLNTVFRT LASEDIPDLP PGGGLDCKAT VIAEVYSQIC QVSEECGEKG QDGAGKSNPT HLGSALDMEA
Explore Probable protein phosphatase 1N with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets